Zelira Therapeutics has launched ZYRAYDI™, a patented technology that transforms cannabis distillate into a free flow powder matrix, facilitating the production of pharmaceutical-grade capsules and tablets. This Enhanced Distillate Capture and Dissolution Matrix (EDCDM) addresses formulation challenges and improves dissolution rates, potentially enhancing the acceptance of cannabinoid medicines. ZYRAYDI™ is cost-effective, adaptable, and utilizes FDA-approved ingredients. Zelira's cannabinoid products target various medical conditions, generating revenues from its proprietary formulations in select markets.
Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF) announced that its insomnia medication, Zenivol™, has received approval from Germany's regulatory authority BfArM for launch in the medical cannabis market. This marks a significant milestone as Germany is a major market for cannabinoid-based medicines. Zenivol™ is the world's first clinically validated cannabis-based pharmaceutical sleep medication, already available in Australia. The company aims to collaborate with Adjupharm for its launch in Germany and plans to license Zenivol™ in other global markets.
Zelira Therapeutics Ltd (OTCQB: ZLDAF) launched its RAF FIVE™ acne treatment product line in the US through its dermatology subsidiary, Ilera Derm LLC. This line targets the $11 billion global acne medication market and includes five products enriched with skincare ingredients such as hyaluronic acid and peptides. The unique formulation features Zylorma®, a patent-pending complex developed in collaboration with Dr. Karyn Grossman, utilizing CBD and salicylic acid to combat acne. Initial consumer studies indicate significant improvement in acne symptoms within just seven days.